PITTSBURGH, June 6, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. demonstrated data supporting the utility of cell line-derived multi-gene predictors in the prediction of preoperative chemotherapy response in early stage breast cancer at the 2011 ASCO Annual Meeting on June 4, 2011 in Chicago, Illinois. The study, titled, Multigene Predictors Developed on Breast Cancer Cell Lines to Predict Patient Chemotherapy Response: A Validation Study on the NSABP B-27 Trial, combined the genomic profiles of cell lines with their in vitro chemoresponse data to identify genes whose expression was associated with drug response. The resulting MGP was used to predict chemotherapy response in patients.
"Clinical interests currently lie in identifying patients most responsive to specific chemotherapy agents to maximize the benefit of treatment and to minimize unnecessary side effects," stated Kui Shen, Ph.D., a bioinformatics scientist and co-author of the study. "By combining ChemoFx® chemosensitivity data from cell lines with their genomic profiles, Precision has developed a procedure to derive gene signatures that may predict a patient's chemotherapy response prior to treatment. This approach is now confirmed using NSABP B-27 clinical data, showing an accuracy of as high as 75%."
Precision continues to seek and develop strategic products that fit within the cancer care continuum, including multi-gene predictors to help with choosing treatments for triple negative women. Precision has completed 12 separate validations including both NSABP and U.S. Oncology trials.
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum.
Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy.
Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit www.precisiontherapeutics.com, or www.chemofx.com.
|SOURCE Precision Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved